Keros Therapeutics, Inc.
Datakwaliteit: 100%
KROS
NASDAQ
Manufacturing
Chemicals
€ 11,72
▲
€ 0,01
(0,09%)
6 months return
—
Momentum
Neutral
5Y revenue growth
86,63%
Groei
Revenue Growth (5Y)
86,63%
Boven sectorgemiddelde (1,72%)
Revenue (1Y)6769,41%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
12,34%
Boven sectorgemiddelde (-54,68%)
ROIC8,88%
Net Margin35,68%
Op. Margin27,71%
Veiligheid
Debt / Equity
N/A
Current Ratio29,86
Interest CoverageN/A
Waardering
PE (TTM|NTM)
4,39 | -2,32
Boven sectorgemiddelde (-1,49)
P/B Ratio0,54
EV/EBITDA-4,61
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue grew 86,63% annually over 5 years — strong growth
ROE of 12,34% — decent returns on equity
Net margin of 35,68% shows strong profitability
Generating 105,95 M in free cash flow
P/E of 4,39 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 6682,78%
Price History
Financiële Trends
Koersdoel Analisten
7 analisten
Buy
+92.6%
upside to target
Huidig
€ 11,72
Consensus Target
€ 22,57
€ 16,00
Laag
€ 30,00
Hoog
Vooruitzicht
Forward K/W
-2,32
Forward WPA
-€ 5,05
Omzet Sch.
11,44 M
Winstverassingen
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -€ 0,92
·
Rev Est: 1,50 M
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | € 3,62 | -€ 0,76 | -€ 0,18 | -€ 0,86 | — | — |
| Estimate | € 0,01 | -€ 1,13 | -€ 0,92 | -€ 0,45 | -€ 0,92 | -€ 1,16 |
| Verrassing | +48166,67% | +32,54% | +80,46% | -90,40% | — | — |
Growth
Rev 5Y: 86,63% · Earnings 1Y: N/A
Growth
Rev 5Y: 86,63% · Earnings 1Y: N/A| Revenue Growth (1Y) | 6769,41% | Revenue Growth (3Y) | 3918,70% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 86,63% | Earnings Growth (5Y) | N/A |
Profitability
ROE: 12,34% · Net Margin: 35,68%
Profitability
ROE: 12,34% · Net Margin: 35,68%| Revenue (TTM) | 243,86 M | Net Income (TTM) | 87,01 M |
| ROE | 12,34% | ROA | 11,60% |
| Gross Margin | N/A | Operating Margin | 27,71% |
| Net Margin | 35,68% | Free Cash Flow (TTM) | 105,95 M |
| ROIC | 8,88% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 29,86
Safety
D/E: N/A · Current: 29,86| Debt / Equity | N/A | Current Ratio | 29,86 |
| Interest Coverage | N/A | Asset Turnover | 0,33 |
| Working Capital | 695,22 M | Tangible Book Value | 703,58 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: 4,39 · EV/EBITDA: -4,61
Valuation
P/E: 4,39 · EV/EBITDA: -4,61| P/E Ratio | 4,39 | Forward P/E | -2,32 |
| P/B Ratio | 0,54 | P/S Ratio | 1,57 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | -4,61 | Fwd EV/EBITDA | N/A |
| Forward P/S | 33,36 | Fwd Earnings Yield | N/A |
| FCF Yield | 27,76% | ||
| Market Cap | 381,74 M | Enterprise Value | -311,73 M |
Per Share
EPS: 2,30 · FCF/Share: 3,48
Per Share
EPS: 2,30 · FCF/Share: 3,48| EPS (Diluted TTM) | 2,30 | Revenue / Share | 8,00 |
| FCF / Share | 3,48 | OCF / Share | 3,53 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 121,77% · CapEx/Rev: 0,64%
Efficiency
FCF Conv: 121,77% · CapEx/Rev: 0,64%| CapEx / Revenue | 0,64% | FCF Conversion | 121,77% |
| SBC-Adj. FCF | 75,75 M | Growth Momentum | 6682,78 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 243,86 M | 3,55 M | 151.000,0 | 0,0 | 20,10 M |
| Net Income | 87,01 M | -187,35 M | -152,99 M | -104,68 M | -58,74 M |
| EPS (Diluted) | 2,30 | -5,00 | -5,20 | -4,15 | -2,52 |
| Gross Profit | — | — | — | — | — |
| Operating Income | 67,57 M | -210,83 M | -169,94 M | -114,79 M | -56,37 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 129,64 M | 173,63 M | 135,26 M | 87,27 M | 55,14 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | 0,0 | 0,0 | 1.000,0 | 4.000,0 |
| Income Tax | 4,88 M | 300.000,0 | 0,0 | 0,0 | 2,01 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 338,02 M | 615,89 M | 370,03 M | 306,78 M | 255,25 M |
| Total Liabilities | 34,89 M | 44,33 M | 37,81 M | 29,36 M | 12,08 M |
| Shareholders' Equity | 303,13 M | 571,55 M | 332,21 M | 277,42 M | 243,17 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 287,42 M | 559,93 M | 331,15 M | 279,05 M | 230,04 M |
| Current Assets | 315,43 M | 588,89 M | 347,29 M | 285,77 M | 251,44 M |
| Current Liabilities | 20,41 M | 27,45 M | 24,37 M | 16,55 M | 11,85 M |
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers)
Vergeleken met vergelijkbare bedrijven in Manufacturing
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers) Vergeleken met vergelijkbare bedrijven in Manufacturing| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 4,4 | -1,5 |
| P/B | 0,5 | 1,6 |
| ROE % | 12,3 | -54,7 |
| Net Margin % | 35,7 | -41,5 |
| Rev Growth 5Y % | 86,6 | 1,7 |
| D/E | — | 0,3 |
{"event":"ticker_viewed","properties":{"ticker":"KROS","listing_kind":"stock","pathname":"/stocks/kros","exchange":"NASDAQ","country":"US"}}